HUP0302339A2 - Emlõs receptoralegység-fehérjék, megfelelõ reagensek és eljárások - Google Patents

Emlõs receptoralegység-fehérjék, megfelelõ reagensek és eljárások

Info

Publication number
HUP0302339A2
HUP0302339A2 HU0302339A HUP0302339A HUP0302339A2 HU P0302339 A2 HUP0302339 A2 HU P0302339A2 HU 0302339 A HU0302339 A HU 0302339A HU P0302339 A HUP0302339 A HU P0302339A HU P0302339 A2 HUP0302339 A2 HU P0302339A2
Authority
HU
Hungary
Prior art keywords
subject
methods
dcrs5
immune system
receptor subunit
Prior art date
Application number
HU0302339A
Other languages
English (en)
Inventor
Madaline Chirica
Robert A. Kastelein
Kevin W. Moore
Christi L. Parham
Original Assignee
Schering Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22753958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0302339(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp. filed Critical Schering Corp.
Publication of HUP0302339A2 publication Critical patent/HUP0302339A2/hu
Publication of HUP0302339A3 publication Critical patent/HUP0302339A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Abstract

A találmány tárgyát képezik emlősszervezet fiziológiáját, beleértve azimmunrendszer funkcióját befolyásolni képes készítmények és eljárások.A találmány tárgyát képezik eljárások a fejlődés és/vagy azimmunrendszer szabályzására. A találmány tárgyát citokinreceptorokkalrokon szerkezetű, új receptorok, például főemlősből származó,citokinreceptorszerű molekuláris struktúrák képezik, melyek elnevezéseDNAX citokinreceptor-alegységek (DCRS), különösen egy alegység, aDCRS5-jelű, valamint biológiai aktivitásaik. A találmány tárgyátképezik magukat a polipeptideket kódoló nukleinsavak, éselőállításukra szolgáló eljárások és alkalmazásuk. Továbbá a találmánytárgyát képezi a p40/IL-B30-ligandum párosíthatósága a DCRS5- és IL-12Rb1-receptoralegységekkel, amely párosodás betekintést biztosítspecifikus agonistákat és antagonistákat alkalmazó indikációkba.Szintén a találmány tárgyát képezik ilyen anyagok diagnosztikai ésterápiás alkalmazásai. Ó
HU0302339A 2000-05-10 2001-05-10 Mammalian receptor subunit proteins, related reagents and methods HUP0302339A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20342600P 2000-05-10 2000-05-10
PCT/US2001/015057 WO2001085790A2 (en) 2000-05-10 2001-05-10 Mammalian cytokine receptor subunit proteins, related reagents and methods

Publications (2)

Publication Number Publication Date
HUP0302339A2 true HUP0302339A2 (hu) 2003-10-28
HUP0302339A3 HUP0302339A3 (en) 2011-01-28

Family

ID=22753958

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302339A HUP0302339A3 (en) 2000-05-10 2001-05-10 Mammalian receptor subunit proteins, related reagents and methods

Country Status (25)

Country Link
US (7) US6756481B2 (hu)
EP (3) EP1918377B1 (hu)
JP (6) JP5073909B2 (hu)
KR (1) KR100869621B1 (hu)
CN (2) CN101654479A (hu)
AT (1) ATE396264T1 (hu)
AU (2) AU6135101A (hu)
CA (1) CA2408571C (hu)
CY (1) CY1108545T1 (hu)
CZ (1) CZ304022B6 (hu)
DE (1) DE60134136D1 (hu)
DK (1) DK1287130T3 (hu)
ES (1) ES2307618T3 (hu)
HK (1) HK1049862B (hu)
HU (1) HUP0302339A3 (hu)
IL (2) IL152414A0 (hu)
MX (1) MXPA02011081A (hu)
NO (2) NO331408B1 (hu)
NZ (1) NZ522146A (hu)
PL (1) PL209128B1 (hu)
PT (1) PT1287130E (hu)
SI (1) SI1287130T1 (hu)
SK (1) SK287984B6 (hu)
WO (1) WO2001085790A2 (hu)
ZA (1) ZA200208795B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082734A1 (en) * 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
PT1188830E (pt) 1999-06-02 2010-04-09 Chugai Pharmaceutical Co Ltd Nova proteína nr10 receptora da hemopoietina
WO2001023556A1 (fr) * 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Nouvelle proteine receptrice d'hemopoietine (nr12)
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
NZ522146A (en) * 2000-05-10 2004-10-29 Schering Corp Mammalian receptor-like proteins, designated DNAX cytokine receptor subunits (DCRS), in particular DCRS5
NZ539271A (en) 2002-10-30 2008-12-24 Genentech Inc Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23)
EP1587834B1 (en) 2002-12-23 2011-07-06 Schering Corporation Uses of il-23 mammalian cytokine; related reagents
US20040219150A1 (en) * 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
WO2004081190A2 (en) * 2003-03-10 2004-09-23 Schering Corporation Uses of il-23 agonists and antagonists; related reagents
CN101052726A (zh) 2003-05-09 2007-10-10 森托科尔公司 IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
BRPI0507794A (pt) * 2004-02-17 2007-07-17 Schering Corp métodos de modular a atividade de il-23, reagentes relacionados
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
MXPA06012754A (es) * 2004-05-03 2007-02-19 Schering Corp El uso de la expresion de il-17 para predecir la inflamacion de la piel: metodos de tratamiento.
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
EP2292758A3 (en) * 2004-12-20 2013-12-25 Merck Sharp & Dohme Corp. Uses of mammalian cytokine; related reagents
JP2009501006A (ja) 2005-06-30 2009-01-15 セントカー・インコーポレーテツド 抗ｉｌ−２３抗体、組成物、方法および用途
PL1971366T3 (pl) * 2005-12-29 2015-01-30 Janssen Biotech Inc Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
BRPI0712426B1 (pt) 2006-06-08 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Usos de um anticorpo anti-nr10/il-31ra com atividade neutralizante de nr10/il-31ra, de um fragmento e/ou um fragmento quimicamente modificado do anticorpo e de um agente
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
NZ579297A (en) * 2007-02-28 2012-03-30 Schering Corp Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders
BRPI0807991A2 (pt) * 2007-02-28 2014-06-17 Schering Corp Anticorpos anti-il-23r elaborados.
EP2241332A4 (en) 2007-12-05 2011-01-26 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT AGAINST PRITURE
KR20110025649A (ko) 2008-05-05 2011-03-10 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
WO2010027767A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies
WO2010112458A1 (en) * 2009-03-31 2010-10-07 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
RS55161B1 (sr) 2010-11-04 2017-01-31 Boehringer Ingelheim Int Anti-il-23 antitela
NZ700802A (en) 2012-05-03 2017-06-30 Boehringer Ingelheim Int Anti-il-23p19 antibodies
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
TWI711629B (zh) 2014-09-03 2020-12-01 德商包林格因蓋爾漢國際股份有限公司 靶向IL-23A與TNF-α之化合物及其用途
MX2021005905A (es) 2018-11-20 2021-06-23 Janssen Biotech Inc Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1319315A (en) 1969-06-19 1973-06-06 Citizen Watch Co Ltd Calendar timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US5888774A (en) 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
JPH11273358A (ja) 1998-03-26 1999-10-08 Kawasaki Steel Corp 半導体記憶装置
US20030082734A1 (en) 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
SI1181366T2 (sl) * 1999-06-01 2013-10-30 Merck Sharp & Dohme Corp. Sesalski receptorski proteini; sorodni reagenti in postopki
WO2001018051A2 (en) * 1999-09-09 2001-03-15 Schering Corporation Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
WO2001023556A1 (fr) 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Nouvelle proteine receptrice d'hemopoietine (nr12)
JP2008099690A (ja) 1999-09-27 2008-05-01 Chugai Pharmaceut Co Ltd 新規ヘモポエチン受容体蛋白質、ｎｒ１２
NZ522146A (en) * 2000-05-10 2004-10-29 Schering Corp Mammalian receptor-like proteins, designated DNAX cytokine receptor subunits (DCRS), in particular DCRS5

Also Published As

Publication number Publication date
WO2001085790A3 (en) 2002-07-18
JP2012187111A (ja) 2012-10-04
CA2408571A1 (en) 2001-11-15
ES2307618T3 (es) 2008-12-01
JP2015110576A (ja) 2015-06-18
EP1918377B1 (en) 2013-12-04
US7964703B2 (en) 2011-06-21
US20090060865A1 (en) 2009-03-05
EP2275548A1 (en) 2011-01-19
SK287984B6 (sk) 2012-08-06
WO2001085790A2 (en) 2001-11-15
MXPA02011081A (es) 2003-03-10
HUP0302339A3 (en) 2011-01-28
CN1575337A (zh) 2005-02-02
DK1287130T3 (da) 2008-09-01
EP1287130B1 (en) 2008-05-21
JP5073909B2 (ja) 2012-11-14
CZ304022B6 (cs) 2013-08-28
NO20025354D0 (no) 2002-11-08
NZ522146A (en) 2004-10-29
PT1287130E (pt) 2008-09-01
US20050100917A1 (en) 2005-05-12
EP1287130B2 (en) 2017-07-26
EP1287130A2 (en) 2003-03-05
US20100261273A1 (en) 2010-10-14
SK15742002A3 (sk) 2003-03-04
US7510853B2 (en) 2009-03-31
JP2008273961A (ja) 2008-11-13
EP1918377A1 (en) 2008-05-07
NO20111147L (no) 2003-01-10
JP2015057396A (ja) 2015-03-26
US7749718B2 (en) 2010-07-06
DE60134136D1 (de) 2008-07-03
US20030017617A1 (en) 2003-01-23
US20110243842A1 (en) 2011-10-06
ATE396264T1 (de) 2008-06-15
KR100869621B1 (ko) 2008-11-21
PL365177A1 (en) 2004-12-27
US6756481B2 (en) 2004-06-29
HK1049862B (zh) 2008-08-01
IL152414A (en) 2010-05-31
HK1049862A1 (en) 2003-05-30
PL209128B1 (pl) 2011-07-29
SI1287130T1 (sl) 2008-08-31
CY1108545T1 (el) 2014-04-09
CZ20023698A3 (cs) 2003-04-16
CN101654479A (zh) 2010-02-24
CA2408571C (en) 2014-04-29
JP2003532408A (ja) 2003-11-05
JP2012070740A (ja) 2012-04-12
AU6135101A (en) 2001-11-20
AU2001261351B2 (en) 2007-03-01
US20120121601A1 (en) 2012-05-17
NO331408B1 (no) 2011-12-19
IL152414A0 (en) 2003-05-29
US20050100918A1 (en) 2005-05-12
US7411041B2 (en) 2008-08-12
KR20020092472A (ko) 2002-12-11
US8110378B2 (en) 2012-02-07
NO20025354L (no) 2003-01-10
ZA200208795B (en) 2004-02-09

Similar Documents

Publication Publication Date Title
HUP0302339A2 (hu) Emlõs receptoralegység-fehérjék, megfelelõ reagensek és eljárások
Barton IL-6: insights into novel biological activities.
Braden et al. Soft lining materials--a review.
Robledo et al. Signaling of the cardiotrophin-1 receptor: evidence for a third receptor component
Weber-Nordt et al. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain
Drachman et al. The c-Mpl ligand (Thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl (∗)
Luo et al. A hierarchical cascade of second messengers regulates Pseudomonas aeruginosa surface behaviors
Kotenko et al. Other kinases can substitute for Jak2 in signal transduction by interferon-γ
Pandey et al. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin
Schröder et al. Non-canonical interleukin 23 receptor complex assembly: p40 protein recruits interleukin 12 receptor β1 via site II and induces p19/interleukin 23 receptor interaction via site III
Aman et al. cDNA cloning and characterization of the human interleukin 13 receptor α chain
Myers et al. Expression of functional RANK on mature rat and human osteoclasts
Bacon et al. Thrombopoietin (TPO) induces tyrosine phosphorylation and activation of STAT5 and STAT3
HUP0301102A2 (hu) Emlős citokinok; kapcsolódó reagensek és eljárások
ES2173922T3 (es) Polipeptidos de la familia del gen de la semaforina.
Rose-John et al. “Family reunion”–A structured view on the composition of the receptor complexes of interleukin-6-type and interleukin-12-type cytokines
DE69638050D1 (de) Hemopoietin-rezeptor und dafür kodierende genetische sequenzen
Dams-Kozlowska et al. A designer hyper interleukin 11 (H11) is a biologically active cytokine
Adam et al. Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor
Piossek et al. Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF
Seldin et al. Mutational analysis of a critical signaling domain of the human interleukin 4 receptor.
DK1064376T3 (da) GFR-alpha3 og dets anvendelser
AU1208497A (en) Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
Li et al. Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and-independent signaling
Müller-Newen et al. Studies on the interleukin-6-type cytokine signal transducer gp130 reveal a novel mechanism of receptor activation by monoclonal antibodies

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): SCHERING CORP., US

FC4A Lapse of provisional application due to refusal